FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206739381> ?p ?o ?g. }

• W4206739381 endingPage "378" @default.
• W4206739381 startingPage "378" @default.
• W4206739381 abstract "Metastatic urothelial carcinoma (mUC) remains an incurable disease with limited treatment options after platinum-based chemotherapy and immune checkpoint blockade (ICB). Vinflunine has shown a modest increase in overall survival and remains a therapeutic option for chemo- and immunotherapy refractory tumours. However, biomarkers that could identify responding patients to vinflunine and possible alternative therapies after failure to treatment are still missing. In this study, we aimed to identify potential genomic biomarkers of vinflunine response in mUC patient samples and potential management alternatives.Formalin-fixed paraffin-embedded samples of mUC patients (n = 23) from three university hospitals in Spain were used for genomic targeted-sequencing and transcriptome (using the Immune Profile panel by NanoString) analyses. Patients who received vinflunine after platinum-based chemotherapy failure were classified in non-responders (NR: progressive disease ≤ 3 months; n= 11) or responders (R: response ≥ 6 months; n = 12).Genomic characterization revealed that the most common alteration, TP53 mutations, had comparable frequency in R (6/12; 50%) and NR (4/11; 36%). Non-synonymous mutations in KTM2C (4/12; 33.3%), PIK3CA (3/12; 25%) and ARID2 (3/12; 25%) were predominantly associated with response. No significant difference was observed in tumour mutational burden (TMB) between R and NR patients. The NR tumours showed increased expression of diverse immune-related genes and pathways, including various interferon gamma-related genes. We also identified increased MAGEA4 expression as a potential biomarker of non-responding tumours to vinflunine treatment.Our data may help to identify potential genomic biomarkers of response to vinflunine. Moreover, tumours refractory to vinflunine showed immune signatures potentially associated with response to ICB. Extensive validation studies, including longitudinal series, are needed to corroborate these findings." @default.
• W4206739381 created "2022-01-26" @default.
• W4206739381 creator A5011244404 @default.
• W4206739381 creator A5011885884 @default.
• W4206739381 creator A5014473319 @default.
• W4206739381 creator A5015501065 @default.
• W4206739381 creator A5019213894 @default.
• W4206739381 creator A5020299093 @default.
• W4206739381 creator A5024147987 @default.
• W4206739381 creator A5033288267 @default.
• W4206739381 creator A5036063886 @default.
• W4206739381 creator A5044977963 @default.
• W4206739381 creator A5047828205 @default.
• W4206739381 creator A5049189732 @default.
• W4206739381 creator A5054850662 @default.
• W4206739381 creator A5063883661 @default.
• W4206739381 creator A5066684629 @default.
• W4206739381 creator A5070674443 @default.
• W4206739381 creator A5071711554 @default.
• W4206739381 creator A5074076730 @default.
• W4206739381 creator A5074105722 @default.
• W4206739381 creator A5077092134 @default.
• W4206739381 creator A5090567596 @default.
• W4206739381 creator A5091292060 @default.
• W4206739381 creator A5091301435 @default.
• W4206739381 date "2022-01-13" @default.
• W4206739381 modified "2023-10-16" @default.
• W4206739381 title "Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer" @default.
• W4206739381 cites W1973213475 @default.
• W4206739381 cites W2076198632 @default.
• W4206739381 cites W2093773243 @default.
• W4206739381 cites W2102116016 @default.
• W4206739381 cites W2103192876 @default.
• W4206739381 cites W2103433909 @default.
• W4206739381 cites W2129172946 @default.
• W4206739381 cites W2131178190 @default.
• W4206739381 cites W2131546932 @default.
• W4206739381 cites W2151488185 @default.
• W4206739381 cites W2154029052 @default.
• W4206739381 cites W2201306698 @default.
• W4206739381 cites W2289712604 @default.
• W4206739381 cites W2564452722 @default.
• W4206739381 cites W2588916311 @default.
• W4206739381 cites W2614443510 @default.
• W4206739381 cites W2738200477 @default.
• W4206739381 cites W2784433559 @default.
• W4206739381 cites W2806784182 @default.
• W4206739381 cites W2889646458 @default.
• W4206739381 cites W2898789672 @default.
• W4206739381 cites W2949857618 @default.
• W4206739381 cites W3012478583 @default.
• W4206739381 cites W3087464965 @default.
• W4206739381 cites W3127912627 @default.
• W4206739381 cites W4294216483 @default.
• W4206739381 cites W4313635027 @default.
• W4206739381 doi "https://doi.org/10.3390/cancers14020378" @default.
• W4206739381 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35053540" @default.
• W4206739381 hasPublicationYear "2022" @default.
• W4206739381 type Work @default.
• W4206739381 citedByCount "1" @default.
• W4206739381 countsByYear W42067393812022 @default.
• W4206739381 crossrefType "journal-article" @default.
• W4206739381 hasAuthorship W4206739381A5011244404 @default.
• W4206739381 hasAuthorship W4206739381A5011885884 @default.
• W4206739381 hasAuthorship W4206739381A5014473319 @default.
• W4206739381 hasAuthorship W4206739381A5015501065 @default.
• W4206739381 hasAuthorship W4206739381A5019213894 @default.
• W4206739381 hasAuthorship W4206739381A5020299093 @default.
• W4206739381 hasAuthorship W4206739381A5024147987 @default.
• W4206739381 hasAuthorship W4206739381A5033288267 @default.
• W4206739381 hasAuthorship W4206739381A5036063886 @default.
• W4206739381 hasAuthorship W4206739381A5044977963 @default.
• W4206739381 hasAuthorship W4206739381A5047828205 @default.
• W4206739381 hasAuthorship W4206739381A5049189732 @default.
• W4206739381 hasAuthorship W4206739381A5054850662 @default.
• W4206739381 hasAuthorship W4206739381A5063883661 @default.
• W4206739381 hasAuthorship W4206739381A5066684629 @default.
• W4206739381 hasAuthorship W4206739381A5070674443 @default.
• W4206739381 hasAuthorship W4206739381A5071711554 @default.
• W4206739381 hasAuthorship W4206739381A5074076730 @default.
• W4206739381 hasAuthorship W4206739381A5074105722 @default.
• W4206739381 hasAuthorship W4206739381A5077092134 @default.
• W4206739381 hasAuthorship W4206739381A5090567596 @default.
• W4206739381 hasAuthorship W4206739381A5091292060 @default.
• W4206739381 hasAuthorship W4206739381A5091301435 @default.
• W4206739381 hasBestOaLocation W42067393811 @default.
• W4206739381 hasConcept C104317684 @default.
• W4206739381 hasConcept C121608353 @default.
• W4206739381 hasConcept C126322002 @default.
• W4206739381 hasConcept C143998085 @default.
• W4206739381 hasConcept C150194340 @default.
• W4206739381 hasConcept C162317418 @default.
• W4206739381 hasConcept C2776694085 @default.
• W4206739381 hasConcept C2777701055 @default.
• W4206739381 hasConcept C2780352672 @default.
• W4206739381 hasConcept C2780851360 @default.
• W4206739381 hasConcept C2781197716 @default.
• W4206739381 hasConcept C502942594 @default.

• next